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Abstract 
Background: The exosomal nucleic acid (exoNA) from the plasma and pleural fluid can potentially provide means to 
identify genomic changes in non‑small cell lung cancer (NSCLC) patients who develop resistance to targeted epider‑
mal growth factor receptor (EGFR) inhibitor therapy.
Methods: We compared the performance of the following tools to detect EGFR mutations in 54 plasma samples and 
13 pleural fluid using cfDNA, combined TNA (exoTNA + cfTNA), or total cellular DNA: droplet digital PCR (ddPCR), the 
Cobas® EGFR Mutation Test v2 (Cobas) and NGS with Oncomine Pan‑Cancer Cell‑Free Assay.
Results: All three of these platforms demonstrated 100% specificity in the detection of EGFR mutations in the 
plasma. In the detection of an activating mutation (exon 19 deletion and L858R), Cobas using cfDNA, ddPCR using 
combined TNA, and NGS using combined TNA showed a sensitivity of 93, 95.3, and 93.8%, respectively. For T790M 
mutation detection, the Cobas, ddPCR, and NGS showed a sensitivity of 64.7, 88.2, and 93.3%, respectively. Pleural 
fluid analysis revealed enrichment of the T790M mutant copies in the exosomes. ddPCR using exoTNA showed higher 
sensitivity than did total cellular DNA from the pleural fluid.
Conclusion: These results demonstrated that combined TNA in the plasma and exoTNA in the pleural fluid can be 
used to evaluate low‑abundant EGFR mutant copies in NSCLC.
Keywords: Liquid biopsy, Extracellular vesicles, Circulating tumor DNA, Non‑small cell lung cancer, Epidermal growth 
factor receptor, Tyrosine kinase inhibitors
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Background
The discovery of driver mutations in the epidermal 
growth factor receptor (EGFR) gene has led to a dramatic 
paradigm shift in the therapeutic strategies for advanced 
non-small-cell lung cancer (NSCLC). First- and second-
generation tyrosine kinase inhibitors (TKIs), such as 
gefitinib, erlotinib, and afatinib, are standard therapies 
for patients with advanced NSCLC harboring mutations 
in EGFR. These mutations include deletion mutations in 
exon 19 and the L858R mutation in exon 21 [1, 2]. Unfor-
tunately, acquired resistance to TKIs frequently develops 
within 1 or 2 years of initiating therapy. The most com-
mon mechanism of resistance, which accounts for ~ 60% 
of cases, is the acquired mutation T790M. MET ampli-
fication (5–7%) and ERBB2 amplification (5–13%) occur 
less frequently than do the T790M mutation [3–5].
Most commonly, a cancer’s molecular profile 
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surveillance of clonal evolution, including acquired 
resistance alterations following TKI therapy, is essen-
tial for precision medicine. This frequent surveillance 
cannot be effectively achieved using tissue biopsy 
specimens, however, due to the possibility of inappro-
priate or inadequate sampling that misses portions of 
the tumor that are developing treatment resistance or 
have acquired new driver mutations due to tumor het-
erogeneity [6]. Therefore, liquid biopsy samples are 
considered an alternative means of detecting clinically 
relevant mutations in NSCLC patients undergoing TKI 
therapy [7].
Circulating tumor DNA (ctDNA) is the most com-
monly analyzed DNA to detect EGFR mutations in 
NSCLC [8]. Many technical platforms targeting ctDNA 
are already being implemented in clinical practice. 
However, the low abundance of ctDNA is an obsta-
cle for detecting EGFR mutations in NSCLC patients 
with acquired TKI-resistance. In particular, patients 
with a low T790M copy number (< 10 copies/mL) have 
similar responses to osimertinib than do those with a 
higher T790M copy number (≥ 10 copies/mL) [9]. In 
one study, there were more patients with low T790M 
copy numbers than there were with higher T790M copy 
numbers [10]. Therefore, the pre-analytical steps for 
maximizing the tumor-derived nucleic acid concen-
tration and ultra-sensitive analytical techniques were 
essentially required to achieve the optimal sensitivity of 
the EGFR mutation.
Exosomal nucleic acid (exoNA) has been studied as a 
target for cancer mutation testing. It has been shown 
to improve the sensitivity of detection in patients 
with limited T790M mutant copies of cell-free DNA 
(cfDNA), such as those with early-stage NSCLC or 
intrathoracic disease (M0/M1a) [7, 8, 11, 12]. Further-
more, body fluids such as bronchoalveolar lavage (BAL) 
and pleural fluids also have been tested to assess the 
feasibility of detecting EGFR mutations. These fluids 
have also been evaluated to determine which compo-
nent (exosome, supernatant, and cell pellet) contained 
abundant tumor-derived nucleic acids in NSCLC 
patients [13, 14].
There is a constant need to improve the detection 
capability of clinically significant, but rare mutant alleles 
in clinical samples. Therefore, we compared the perfor-
mance of different techniques (allele-specific real-time 
PCR, droplet digital PCR, and next-generation sequenc-
ing) using various sources of tumor-derived nucleic acids 
(cfDNA and exosome from plasma, exosome and total 
cellular DNA from pleural fluid). We demonstrated the 
optimal analytical method to improve the sensitivity of 




Patients were included in the two following criteria were 
all met: (1) they had a diagnosis of NSCLC and con-
firmed EGFR mutation on tissue genotyping, and (2) 
showed disease progression on first- or second-genera-
tion EGFR-TKI. Between November 2017 and September 
2019, 64 consecutive NSCLC patients were prospectively 
enrolled. The EGFR genotyping result of tissue (n = 61) 
was obtained from specimens at initial diagnosis (n = 58) 
or from specimens matched with plasma (n = 3). Patients 
consented to the protocol approved by the Institutional 
Review Board of Gangnam Severance Hospital and 
Kangnam Sacred Heart Hospital. Fifty-four whole blood 
samples were obtained from 54 patients, and 13 pleural 
fluids was obtained from 13 patients. Three pleural fluid 
and blood samples were collected at the same time in 
three patients (P23, P25, and P54).
Preparation of nucleic acid from plasma and cDNA 
synthesis
The blood samples were collected in cell-free DNA Blood 
Collection Tubes (Roche, Pleasanton, CA, USA). Plasma 
isolation was performed using a two-step plasma separa-
tion procedure. The blood samples were centrifuged at 
1200 g for 10 min, followed by high-speed centrifugation 
at 16,000 g for 10 min. The plasma aliquots were stored at 
− 80 °C [15].
Exosomes were isolated from the plasma using Exo-
Quick™ (System Biosciences, Mountain View, CA, USA). 
We extracted the plasma cfDNA and exosomal total 
nucleic acid (exoTNA) using the MagMAX™ Cell-Free 
DNA Isolation Kit (Thermo Fisher Scientific, Waltham, 
MA, USA) and MagMAX™ Total Nucleic Acid Isolation 
Kit (Thermo Fisher Scientific), respectively [11]. The con-
centrations of cfDNA and exoTNA were assessed with 
the Qubit™ 3.0 Fluorometer using the Qubit™ dsDNA 
HS Assay Kit (Thermo Fisher Scientific). cDNA synthesis 
was performed using a SuperScript™ VILO™ cDNA Syn-
thesis Kit (Invitrogen, Carlsbad, CA, USA).
Preparation of nucleic acid from exosomes, and cell pellets 
and supernatants from pleural fluid
The pleural fluid was centrifuged at 3000  g for 15  min 
to remove cellular debris. The exosomes were isolated 
from the supernatants using ExoQuick™. A nucleic acid 
of exosomes was extracted with the MagMAX™ Total 
Nucleic Acid Isolation Kit. cDNA synthesis was per-
formed using a SuperScript™ VILO™ cDNA Synthesis 
Kit. We extracted the total DNA from the cell pellet using 
the QIAamp DNA Mini Kit (QIAGEN, Hilden, Ger-
many). The sizes of the DNA fragments in the exosomes 
were assessed using a 2200 TapeStation Instrument 
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(Agilent Technologies, Santa Clara, CA, USA) with the 
Genomic DNA ScreenTape System. The DNA concen-
tration was assessed with the Qubit 3.0 Fluorometer 
(Thermo Fisher Scientific). The RNA yield and size distri-
bution were analyzed using an Agilent 2100 Bioanalyzer 
with an RNA 6000 Pico kit (Agilent Technologies, Foster 
City, CA, USA).
Cobas EGFR Mutation Test v2
For the Cobas EGFR assay, 75  μL of DNA from each 
plasma sample (2  mL) was loaded into three reaction 
wells (25 μL DNA per well). Amplification and detection 
were performed using the Cobas z 480 analyzer (Roche 
Molecular Systems, Inc., Branchburg, NJ, USA). The data 
were interpreted using the Cobas z 480 software if the 
positive and negative controls showed valid results.
Droplet digital PCR (ddPCR)
The ddPCR assays were performed using the Prime-
PCR™ ddPCR™ Mutation Detection Assay kit, and the 
PrimePCR™ ddPCR™ EGFR Exon 19 Deletions Screen-
ing Kit (Bio-Rad Laboratories, Hercules, CA, USA) [11]. 
Tumor-derived nucleic acids (cfDNA and exoTNA) were 
extracted from 1 to 2 mL of plasma or pleural fluid. The 
ddPCR assay for detecting EGFR mutations was vali-
dated using the Multiplex I cfDNA Reference Standards 
(Horizon Discovery, Cambridge, UK) and healthy control 
samples from a previous study [11]. Briefly, the amplifica-
tions were performed in a reaction volume of 20 μL on a 
QX100 Droplet Digital PCR System (Bio-Rad). The 20 μL 
of the PCR mixture was composed of 10 μL Bio-Rad 
Super mix TaqMan, 1–2 μL of each amplification primer/
probe mix, and 8–9 μL of nucleic acids (NAs). Thermal 
cycling comprised an initial denaturing and polymerase 
hot-start activating step of 10 min at 95  °C, followed by 
40 cycles of 95 °C for 30 s and 55 °C for 60 s. The results 
were analyzed with QuantaSoft v.1.7.2 software (Bio-
Rad) and reported as copies per milliliter of plasma. The 
ddPCR assay was validated for detecting EGFR muta-
tions and determining the limit of detection (LOD) in a 
previous study [11]. The assays were considered “posi-
tive” if the measured event rate was ≥ 2 events/assay and 
“negative” if the event rate within a gated region was < 2 
events/assay.
Next‑generation sequencing (NGS)
For NGS, a library was prepared using the Oncomine 
Pan-Cancer Cell-Free Assay (Thermo Fisher Scientific) 
targeting 52 cancer-associated genes (Additional file 1: 
Table  S1). The NGS panel is designed to detect single 
nucleotide variations, small indels, copy-number alter-
ations, and gene fusions. The libraries were prepared 
using > 5 ng nucleic acid input following the Oncomine 
Pan-Cancer Cell-Free Assay user guide. Templating and 
sequencing were performed using the Ion 540™ Kit on 
the Ion Chef™ and on the Ion S5 XL system (Thermo 
Fisher Scientific). Alignment to the hg19 human refer-
ence genome and variant calling were performed using 
the Torrent Suite™ and Ion Reporter™ software ver-
sion 5.10, respectively. The Torrent Suite™ Software 
provided molecular coverage depth and read coverage 
depth at the target base; therefore, this software was 
able to increase the detection sensitivity for low-fre-
quency variants [16, 17].
The average of median read coverage and median 
molecular coverage were 36,095 × and 1934  ×, respec-
tively. Variants with an allele frequency of > 0.1% were 
reported. The measured allele frequency (%) was calcu-
lated as the mutant coverage depth divided by the total 
coverage depth.
Statistical analysis
The statistical analysis was performed using R (version 
3.5.2, http://www.r-proje ct.org) and MedCalc soft-
ware (https ://www.medca lc.org/). The nonparamet-
ric data were analyzed using the Kruskal–Wallis tests. 
Multiple comparisons were made using Dunn’s test. A 
p-value < 0.05 was considered statistically significant.
Results
Patient and tumor characteristics
The baseline clinical and pathological characteristics of 
the 64 patients are described in Table 1. More women 
in our patient cohort than men (73.4% vs. 26.6%) 
might be reflected by the differential distribution of 
EGFR mutation between male and female patients 
with NSCLC, as reported by previous studies [18, 19]. 
Most patients had stage IV disease. Only two patients 
had M0 stage disease. Two patients had T790M muta-
tions in the tissue from a repeat biopsy sample. All of 
the patients received gefitinib, erlotinib, and/or afatinib 
as first line treatment of their advanced or metastatic 
disease.
At the time of progression, patients were tested for 
both the persistence of initial activating mutations (exon 
19 deletion and L858R) and the onset of T790M resist-
ance mutations using the Cobas assay in the plasma 
cfDNA. This testing was performed to determine the 
patients’ eligibility for osimertinib use. The Cobas assay 
showed the persistence of initial activating mutations 
in 41 patients. Among them, T790M resistance muta-
tions were identified in 11 patients (11/41, 26.8%). Four-
teen patients had negative results for both activating and 
resistance mutations.
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Quantification of exoTNA and cfDNA in clinical samples
The cfDNA used in the Cobas® EGFR Mutation Test 
were extracted from plasma samples (2  mL). The 
exoTNA and cfDNA for the ddPCR and NGS were 
extracted from equal volumes of plasma samples from 
54 patients. Among them, three samples were not 
available for NA quantification due to a lack of vol-
ume. The cfDNA amount for the Cobas® EGFR Muta-
tion Test and both exoNA and cfDNA amount for the 
ddPCR assay are depicted in (Additional file  1: Fig. S1). 
The median amount level of cfDNA for the Cobas® 
EGFR Mutation Test was 16.8  ng. Those of cfDNA and 
exoNA for ddPCR were 10.3  ng and 11.41  ng, respec-
tively. There was a significant difference between the NA 
yield of three groups (Kruskal–Wallis test, p = 0.0002). 
There were also significant differences in the NA yield 
between the cfDNA for Cobas® EGFR Mutation Test 
and ExoNA, and the cfDNA for the ddPCR assay 
(p < 0.05, Dunn’s multiple comparisons test).
Comparison among Cobas, ddPCR and NGS using plasma 
from NSCLC patients who progressed under treatment 
with an EGFR‑TKI
We compared the diagnostic performance of Cobas 
(cfDNA), ddPCR (cfDNA + exoTNA), and NGS 
(cfDNA + exoTNA) to detect an EGFR activating muta-
tion (exon 19 deletion and L858R, Table 2) and the resist-
ance T790M mutation (Table 3). NGS was possible in 38 
of 54 cases with sufficient plasma samples. There were 
two patients who were confirmed to have T790M muta-
tions on repeat tissue biopsy (P19 and P40, Additional 
file 1: Table S2). The plasma analysis of one patient (P19) 
revealed positive results from all three platforms (Cobas, 
ddPCR, and NGS). In contrast, plasma analysis in 
another patient (P40) showed negative results in all three 
platforms. Although most patients did not undergo tissue 
re-biopsy, all cases with T790M positivity detected from 
one or more liquid biopsy platforms (Cobas, ddPCR, or 
NGS) had disease progression after > 10  months of TKI 
treatment. Therefore, T790M positivity was defined as 
“true positive,” even if it was detected in only one liquid 
biopsy platform. An activating mutation was considered a 
“true positive” if there was positive detection from two or 
more liquid biopsy platforms, or positive detection from 
tissue genotyping and one or more liquid biopsy plat-
forms. The sensitivities of Cobas, ddPCR, and NGS for 
detection activating mutations in the plasma were 93% 
(95% confidence interval, 91.7–94.3), 95.3% (94–96.6), 
and 93.8 (92.2–95.4), respectively (Table 2). Among three 
samples (P29, P40, P54) with false-negative activating 
mutations according to the Cobas assay, exon 19 deletion 
mutations were detected in two samples. These included 
one mutation from ddPCR (P54, 2 positive droplets/829 
total droplets) and another from NGS (P29, variant allele 
frequency of 0.4%). The NGS assay failed to detect exon 
19 deletion mutations in two samples (P20, P40). Only 
one exon 19 deletion of P20 was detected using both 
Cobas and ddPCR (6 mutant droplets) techniques.
The sensitivities of Cobas, ddPCR, and NGS to detect 
T790M mutations in plasma were 64.7% (95% confi-
dence interval, 63.4–66), 88.2% (86.9–89.5), and 93.3 
(91.7–94.9), respectively (Table  3). Among 17 patients 
Table 1 Patient characteristics
a According to the 8th TMN edition, M1a indicates lung metastases or pleural/
pericardial malignant effusion or nodules; M1b indicates a single metastatic 
lesion in a single distant organ; M1c indicates multiple lesions in a single organ 
or multiple lesions in multiple organs
b Tissue genotyping was performed using the PANAMutyper EGFR kit 
(PANAGENE Inc., Daejeon, Korea)
c Two patients had T790M mutations that were identified though re-biopsy after 
EGFR-TKI therapy
d One exon 20 insertion, one L861Q, one G719X and S768I, and three patients 
with no tissue genotyping result
Other not otherwise specified, TKI tyrosine kinase inhibitor
Clinical characteristics Total 64 
patients, n 
(%)
Age, median (range), years 66 (40–85)
Sex
 Female 47 (73.4)
 Male 17 (26.6)
Histologic type
 Adenocarcinoma 62 (96.9)
 Squamous cell carcinoma 2 (3.1)
Tumor stage
 IIa 1 (1.9)
 IIIb 1 (1.9)
 IVa 36 (66.7)
 IVb 26 (48.1)
M  categorya
 M0 2 (3.1)
 M1a 24 (37.5)
 M1b 15 (23.4)
 M1c 23 (35.9)
Tissue EGFR  genotypingb
 T790M and exon 19  deletionc 2 (3.1)
 Exon 19 deletion 33 (51.6)
 L858R 23 (35.9)
 Otherd 6 (9.4)
Prior treatment
 Gefitinib 34 (53.1)
 Erlotinib 11 (17.2)
 Afatinib 16 (25.0)
 Afatinib + Gefitinib 2 (3.1)
 Erlotinib + Gefitinib 1 (1.6)
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with T790M mutations that were confirmed by tissue 
genotyping and on one additional liquid biopsy platform, 
the Cobas assay did not detect the T790M mutation in 
six patients, although it identified coexisting activating 
mutations in five patients. These false negative T790M 
cases from the Cobas assay consisted of cases with very 
few copies of T790M in the plasma according to the 
results of the ddPCR (3–6 mutant droplets) and NGS 
assays (0.4–1.2% variant allele frequency). However, one 
case (P40) in which T790M was only identified on tis-
sue re-biopsy was excluded (Additional file 1: Table S2). 
In addition, the detection rates of T790M with ddPCR 
(cfDNA + exoTNA) or NGS (cfDNA + exoTNA) were 
as much as 20–30% higher than were those using Cobas 
(cfDNA) (Table 3).
The EGFR T790M mutation is the most frequent muta-
tion associated with the development of acquired resist-
ance to EGFR-TKIs. The T790M was detected in the 
plasma of 17 patients (31.5%) who progressed despite 
treatment with an EGFR-TKI (n = 54). The T790M posi-
tivity rate was 27.8% using ddPCR (15/54), but only 20.4% 
using Cobas (11/54). The genetic alterations related to 
EGFR-TKI tolerance were further explored using NGS 
assay. Seven patients (7/38, 18.4%) were found to have 
resistance mutations other than EGFR T790M. KRAS 
mutations (G12D and G13D) were identified in two 
patients (P28 and P39), and PIK3CA mutations (E545K) 
were found in three patients (P30, P33, and P37). Gene 
amplifications that are associated with TKI resistance 
were identified in two patients (EGFR amplification in P8 
and EGFR/CDK4 amplifications in P52).
Furthermore, six patients (6/38, 15.8%) harbored vari-
ous copies of T790M mutations (2–2098 positive drop-
lets in ddPCR) along with other genetic mutations that 
are known to be associated with TKI resistance (includ-
ing CDK6/KRAS/CCND1 amplifications in P19, PIK3CA 
in P20 and P43, EGFR/CDK6 amplifications in P22, EGFR 
amplification in P23, and BRAF in P50).
Assessment of T790M mutant alleles according to different 
sources of tumor‑derived nucleic acids from pleural fluid
Three pleural fluid samples were used to analyze differ-
ent sources of tumor-derived nucleic acids (exosomes, 
cell pellets, and supernatants) and determine which 
Table 2 Comparing the  detection of  the  EGFR activating mutation between  the  Cobas assay, ddPCR and  NGS using 
plasma from NSCLC patients
a ‘True positive’ was defined as a activating mutation positive in more than two or more liquid biopsy platforms among Cobas, ddPCR, and NGS or positive in tissue 
genotyping and one or more liquid biopsy platforms. ‘True negative’ was defined as activating mutation negative in all tested liquid biopsy platforms
NSCLC non-small cell lung cancer, TP true positive, TN true negative, CI confidence interval
EGFR genotype TP and  TNa (38 cases 
with NGS results)
Cobas assay using cfDNA 
(n = 54)
ddPCR using cfDNA + exoTNA 
(n = 54)
NGS using cfDNA + exoTNA 
(n = 38)
Mutant type Wild‑type Mutant type Wild‑type Mutant type Wild‑type
Mutant type 43 (32) 40 3 41 2 30 2
Wild‑type 11 (6) 0 11 0 11 0 6
Sensitivity,% (95% CI) 93 (91.7–94.3) 95.3 (94–96.6) 93.8 (92.2–95.4)
Specificity, % (95% CI) 100 (98.7–101) 100 (98.7–101) 100 (98.4–102)
Accuracy, % (95% CI) 94.4 (93.1–95.7) 96.3 (95–97.6) 94.7 (93.1–96.3)
Table 3 Performance comparison for detection of the EGFR T790M mutation between the Cobas assay, ddPCR, and NGS 
using plasma from NSCLC patients
a ‘True positive’ was defined as a positive T790M mutation in one or more liquid biopsy platforms among Cobas, ddPCR, and NGS; ‘True negative’ was defined as 
T790M mutation negative in all tested liquid biopsy platforms
NSCLC non-small cell lung cancer, TP true positive, TN true negative, CI confidence interval
EGFR genotype TP and  TNa (38 cases 
with NGS results)
Cobas assay using cfDNA 
(n = 54)
ddPCR using cfDNA + exoTNA 
(n = 54)
NGS using cfDNA + exoTNA 
(n = 38)
Mutant type Wild‑type Mutant type Wild‑type Mutant type Wild‑type
Mutant type 17 (15) 11 6 15 2 14 1
Wild‑type 37 (23) 0 37 0 37 0 23
Sensitivity,% (95% CI) 64.7 (63.4–66) 88.2 (86.9–89.5) 93.3 (91.7–94.9)
Specificity, % (95% CI) 100 (98.7–101) 100 (98.7–101) 100 (98.4–102)
Accuracy, % (95% CI) 88.9 (87.6–90.2) 96.3 (95–97.6) 97.4 (95.8–99)
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compartment was suitable for the analysis. The event 
numbers of T790M positive and wild type cases are 
depicted in (Additional file 1: Fig. S2). Analysis of three 
samples revealed the largest number of mutant copies 
in exoTNA, followed by exoDNA and total DNA from 
the supernatants. In one sample (Sample 2), the total 
DNA from the cell pellet demonstrated the largest num-
ber of mutant copies compared to that in the exoTNA, 
exoDNA, and total DNA from the supernatants. There-
fore, we selected the exoTNA, total cellular DNA and 
tested the pleural fluid samples from 13 NSCLC patients 
with disease progression after EGFR-TKI treatment 
(Additional file 1: Table S3). The ddPCR, using the total 
DNA extracted from the cell pellet, revealed T790M 
mutations in 38.5% of tested pleural fluid samples (5/13) 
(Table  4). Using the exoTNA extracted from the super-
natant, two more cases (P56 and P61) also demonstrated 
T790M positivity (53.8%, 7/13). Two samples showed 
very low mutant copies in ddPCR (including four posi-
tive droplets among 4595 total droplets, and two posi-
tive droplets among 3900 total droplets). Therefore, the 
ddPCR using the total cellular DNA showed 71.4% sensi-
tivity compared with the exoTNA from the supernatant.
The distribution of isolated nucleic acids is shown in 
(Additional file  1: Fig. S3). The high molecular weight 
DNA (10–15  kb long) was more abundant in exosomes 
from pleural fluids than it was from other samples.
Discussion
In this study, we assessed the performance of three liquid 
biopsy platforms (including the Cobas assay, ddPCR, and 
NGS) on different sources of tumor-derived nucleic acids 
(cfDNA, exoTNA, and total DNA) and clinical specimens 
(plasma and pleural fluid). The plasma analysis indi-
cated that a combination of cfDNA and exoTNA showed 
higher sensitivity than that did exoTNA or cfDNA alone. 
In the pleural fluid analysis, exoTNA from supernatants 
showed enrichment of the T790M mutant copies by 
other sources of nucleic acids from supernatants or cell 
pellets.
The advantage of ddPCR is that it can sensitively detect 
low-abundant target molecules. Therefore, ddPCR is 
often used for ctDNA testing [20]. Currently, most liq-
uid biopsy methods used in clinical research and prac-
tice only used cfDNA to detect cancer mutations. Even 
with ddPCR, which is currently considered the most 
sensitive technique, the sensitivity for detecting EGFR 
T790M mutations is only 70–77% of that when using tis-
sue testing if cfDNA is used alone [20, 21]. Therefore, it 
is crucial to increase the sensitivity of the liquid biopsy 
technique to detect resistant mutations and identify 
patients who could potentially benefit from osimerti-
nib therapy. In this study, we found that the sensitivity 
of ddPCR also depends on the type of specimens and 
the sources of nucleic acid. The use of combined TNA 
(cfDNA + exoTNA) in the plasma and exoTNA in the 
pleural fluid allowed for the detection of target mutations 
more sensitively than that using cfDNA or total DNA 
alone.
Both ddPCR and real-time PCR (Cobas) are sensitive 
and relatively easy and fast tests. However, only targeted 
hot-spot mutations are detectable using these tech-
niques. The advantage of NGS, in contrast, is that many 
panel genes can be examined at once to detect known 
resistance mutations of EGFR-TKI other than EGFR hot-
spot mutations. For instance, KRAS, EGFR, and PIK3CA 
mutations are known to be acquired resistance mecha-
nisms to EGFR-TKIs [22, 23]. Amplifications in KRAS, 
EGFR, and cell cycle genes (including CCND1, CDK4, 
and CDK6) have also been reported as TKI resistance 
mechanisms [24, 25]. In this study, we detected muta-
tions in KRAS and PIK3CA, and amplifications in EGFR 
and CDK4 in patients who did not have the EGFR T790M 
mutation.
Table 4 Performance comparison for  the  detection of  the  EGFR T790M mutation between  exoTNA from  supernatant 
and total DNA from cell pellets isolated from pleural fluid (n = 13)
a ‘True positive’ was defined by a positive T790M mutation in one or more liquid biopsy platforms among exoTNA from supernatants and cellular total DNA from 
pleural fluid; ‘True negative’ was defined as T790M mutation negative in all tested liquid biopsy platforms
TP true positive, TN true negative, CI confidence interval
EGFR genotype TP and  TNa ddPCR using exoTNA extracted 
from supernatants
ddPCR using total DNA extracted 
from cell pellet
Mutant type Wild‑type Mutant type Wild‑type
Mutant type 7 7 0 5 2
Wild‑type 6 0 6 0 6
Sensitivity,% (95% CI) 100 (97.3–103) 71.4 (68.7–74.1)
Specificity, % (95% CI) 100 (97.3–103) 100 (97.3–103)
Accuracy, % (95% CI) 100 (97.3–103) 84.6 (81.9–87.3)
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In addition, some patients had other resistance muta-
tions that were found in addition to EGFR T790M. 
The phenomenon by which T790M and other resistant 
mutations occur simultaneously is clonal heterogene-
ity [26]. For instance, the BRAF and PIK3CA mutations 
and EGFR amplification can coexist with T790M in 
patients who progressed despite EGFR-TKI therapy 
[27–29]. The clinical significance of this co-occurring 
mutation is that it can affect the treatment outcomes 
[26].
The size distribution of tumor-derived nucleic acids 
in the exosome may be a critical consideration for 
selecting an extraction method. Our group previously 
showed that a short-length exoTNA (200 bp) contained 
detectable tumor-derived nucleic acids in the exosome 
from a NSCLC patient’s plasma [11]. However, the 
high molecular weight DNA (10–15 kb long) was more 
abundant in the exosomes from pleural fluids in this 
study than it was from the plasma. Therefore, the tar-
get size of the exoNAs depends upon the clinical sam-
ple types, and should be considered in the detection of 
EGFR mutations in NSCLC patients.
One limitation of our study is that matched tissue sam-
pling was not performed in most cases. This might be 
the reason for the lower frequency of T790M mutations 
in our study than the previously reported prevalence of 
40–55% [29]. However, in 22 of 64 patients (34.4%) who 
progressed despite EGFR-TKI therapy, the T790M muta-
tion was identified in one or more liquid biopsy platforms 
(using the plasma or pleural fluid). We identified differ-
ences in the analytical performances of each type of spec-
imen and nucleic acid using data from these patients.
Previous reports suggested that exoNA could be a 
novel DNA source for genetic testing [30]. In our study, 
the distribution of nucleic acid from exosomes was dif-
ferent than that from a cell pellet or supernatant. The 
nucleic acid from exosomes was enriched, high molec-
ular weight DNA. This finding was consistent with that 
from previous reports [13, 30]. Further studies with 
larger cohorts are needed to substantiate our findings.
Conclusion
In conclusion, combined TNA from the plasma and 
exoTNA from the pleural fluid could be used as a fea-
sible target for low-abundant EGFR mutant copies 
in NSCLC. We demonstrated the optimal analytical 
method to improve the sensitivity of detecting EGFR 
mutations in different types of clinical samples.
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